- Home
- CTMX vs LAB Comparison
CTMX vs LAB Comparison
Compare CTMX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- LAB
- Stock Information
- Founded
- CTMX 2008
- LAB 1999
- Country
- CTMX United States
- LAB United States
- Employees
- CTMX N/A
- LAB 818
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- CTMX Health Care
- LAB Industrials
- Exchange
- CTMX Nasdaq
- LAB Nasdaq
- Market Cap
- CTMX 544.2M
- LAB 504.2M
- IPO Year
- CTMX 2015
- LAB 2011
- Fundamental
- Price
- CTMX $3.32
- LAB $1.30
- Analyst Decision
- CTMX Strong Buy
- LAB Buy
- Analyst Count
- CTMX 5
- LAB 2
- Target Price
- CTMX $5.30
- LAB $2.50
- AVG Volume (30 Days)
- CTMX 4.3M
- LAB 1.2M
- Earning Date
- CTMX 11-06-2025
- LAB 10-29-2025
- Dividend Yield
- CTMX N/A
- LAB N/A
- EPS Growth
- CTMX 263.20
- LAB N/A
- EPS
- CTMX 0.49
- LAB N/A
- Revenue
- CTMX $141,100,000.00
- LAB $172,271,000.00
- Revenue This Year
- CTMX N/A
- LAB N/A
- Revenue Next Year
- CTMX N/A
- LAB N/A
- P/E Ratio
- CTMX $6.80
- LAB N/A
- Revenue Growth
- CTMX 18.01
- LAB 76.33
- 52 Week Low
- CTMX $0.40
- LAB $0.92
- 52 Week High
- CTMX $3.49
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- CTMX 75.86
- LAB 48.53
- Support Level
- CTMX $3.11
- LAB $1.25
- Resistance Level
- CTMX $3.39
- LAB $1.38
- Average True Range (ATR)
- CTMX 0.24
- LAB 0.07
- MACD
- CTMX 0.10
- LAB -0.00
- Stochastic Oscillator
- CTMX 90.91
- LAB 26.83
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.